Navigation Links
Cargill Receives Official Notification From FDA Supporting the Safety of Truvia(TM) Rebiana
Date:12/17/2008

anent Acceptable Daily Intake (ADI). (http://www.fao.org/ag/agn/agns/files/jecfa69_final.pdf)

Cargill submitted a GRAS notification to the FDA on May 15, 2008.Prior to this, an independent expert panel convened in March 2008 to review the comprehensive safety dossier for rebiana that also included safety assurance of composition and quality of rebiana. The panel unanimously affirmed that rebiana is safe for its intended use as a general-purpose sweetener. Cargill published all the safety studies for scientific and public comment.

Cargill enlisted leading scientists to design and conduct a rigorous safety evaluation program for Truvia(TM) rebiana - the first such program to test a well-characterized, high-purity form of rebaudioside A. The comprehensive design of the studies and the peer-review process were the foundation of the research program for rebiana. These peer-reviewed, scientific studies, published in the scientific journal Food and Chemical Toxicology establish the safety of Truvia(TM) rebiana. (http://www.truvia.com/media-safety-studies-findings.html) Cargill is the only petitioner to the FDA that has made the safety dossier for rebiana publicly available as part of its GRAS notification.

Stevia is a shrub in the chrysanthemum family that is native to northeastern Paraguay. First discovered by natives of Paraguay, the plant has been grown, harvested and used in South America to sweeten foods and beverages for more than 200 years. The stevia leaf is a good source of natural, zero-calorie sweetness. Due to the fact that there are more than 200 varieties of the stevia plant, all stevia is not the same and stevia products currently on the market vary in their production, composition, purity level and sensory or t
'/>"/>

SOURCE Cargill
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. E. Coli Registry Expanded for Victims of E. Coli Poisoning from Cargill Ground Beef
2. Volunteer for National Suicide Prevention Agency Earns Cargill Award
3. Cargill Executive Joins Blue Cross Board of Trustees
4. ChromaDex Partners With Cargill to Provide Global Quality Control Methods and Standards for Sweet Components of Stevia
5. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
6. DaVita Receives Civil Complaint
7. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
8. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
9. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
10. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
11. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:CAP Deeming Status Renewed 2Health News:Recovered Lyme Disease and US Track and Field Athlete Attends Movie Premiere of LymeLife 2Health News:Recovered Lyme Disease and US Track and Field Athlete Attends Movie Premiere of LymeLife 3Health News:Recovered Lyme Disease and US Track and Field Athlete Attends Movie Premiere of LymeLife 4Health News:Leveraging Cloud Computing is the Latest Offering by ICG Consulting to Streamline Costs While Delivering Robust Business Process Solutions 2Health News:Leveraging Cloud Computing is the Latest Offering by ICG Consulting to Streamline Costs While Delivering Robust Business Process Solutions 3Health News:Mexican health care program successful at reducing crippling health care costs 2Health News:Mexican health care program successful at reducing crippling health care costs 3Health News:Exercise is safe, improves quality of life in patients with chronic heart failure 2Health News:Exercise is safe, improves quality of life in patients with chronic heart failure 3Health News:New Prostate Cancer Drug May Hold Promise 2Health News:New Prostate Cancer Drug May Hold Promise 3
Breaking Medicine Technology:Pharmacy Technician Employment Increasing Up to 32% By 2016 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 3Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 4EcoActive Surfaces Introduces OxiTitan VLR 3A New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 55480 1EcoActive Surfaces Introduces OxiTitan VLR 3A New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 55480 2EcoActive Surfaces Introduces OxiTitan VLR 3A New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 55480 3Lakewood Amedex Inc to Develop Broad Spectrum Influenza Drug to Include H1N1 and H5N1 Type A Strains 4904 1Lakewood Amedex Inc to Develop Broad Spectrum Influenza Drug to Include H1N1 and H5N1 Type A Strains 4904 2Lakewood Amedex Inc to Develop Broad Spectrum Influenza Drug to Include H1N1 and H5N1 Type A Strains 4904 3New Fastrack Technology Improves Productivity 55477 1New Fastrack Technology Improves Productivity 55477 2New Fastrack Technology Improves Productivity 55477 3
Other Medicine Technology:Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 2Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 3Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 4Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 5Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 6Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 7Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 8Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 9Deloitte and Nonprofit Roundtable Host Real-World Disaster Exercise as Next Step in Developing Preparedness Plan for Greater Washington Region 2Deloitte and Nonprofit Roundtable Host Real-World Disaster Exercise as Next Step in Developing Preparedness Plan for Greater Washington Region 3Deloitte and Nonprofit Roundtable Host Real-World Disaster Exercise as Next Step in Developing Preparedness Plan for Greater Washington Region 4